EUVIMEDEUVIMED entdecken
Crossref

Association of Quinolone Exposure in the First‐Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan

Kei Morishita iD, Taku Obara, Tomofumi Ishikawa, Ryo Obara iD, Takamasa Sakai, Noriyuki Iwama, Genki Shinoda, Aoi Noda iD, Masatsugu Orui, Mami Ishikuro, Hiroshi Kawame, Nariyasu Mano und 1 weitere

Pharmacoepidemiology and Drug Safety · 2025-09 · 34 (9)

DOI: 10.1002/pds.70190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 22.08.2025. Verfasst von Kei Morishita und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Epidemiology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. Hauptthemen laut MEDLINE: Abnormalities, Drug-Induced, Quinolones, Anti-Bacterial Agents, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Research Institute of Healthcare Data Science, Ministry of Health, Labour and Welfare of Japan, Ministry of Health, Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the risk of major congenital malformations (MCMs) associated with quinolone exposure during the first trimester of pregnancy using a large administrative database in Japan.

Methods

A large claims database was used from January 2005 to November 2019. The dates of pregnancy onset and delivery were estimated using the developed algorithm. MCMs were defined according to the International Classification of Diseases, 10th revision codes. The risk of MCM associated with first‐trimester quinolone prescriptions was evaluated in women with infectious diseases diagnosed during the first trimester of pregnancy. We evaluated the overall risk of MCMs in infants, and odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by comparing women with first‐trimester prescriptions of quinolones with those without antibiotic prescriptions, adjusting for covariates with propensity score overlap weights.

Results

The prevalence of first‐trimester infectious diseases was 51.6% (47 121/91390). Among 47 121 women diagnosed with infectious diseases, 1 320 were prescribed quinolones during their first trimester of pregnancy. The overall prevalence of MCMs was 6.0% (2282/37766) in women unexposed to antibiotics and 5.9% (78/1320) in those exposed to quinolones. The first‐trimester prescription of quinolone was not significantly associated with the overall MCM prevalence when overlap‐weighted ORs (wOR) were calculated using propensity score overlap weights for covariates (wOR 0.904, 95% CIs 0.684–1.196).

Conclusions

Prescription of quinolones in the first‐trimester of pregnancy was not associated with an increased risk of MCMs in infants. Our findings may support clinical decision‐making when considering quinolone use during the first‐trimester of pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abnormalities, Drug-InducedQuinolonesAnti-Bacterial AgentsPregnancy Complications, InfectiousHumansFemalePregnancyPregnancy Trimester, FirstJapanAdultDatabases, FactualYoung AdultInfant, NewbornPrevalenceRetrospective StudiesRisk Factors

Stichwörter der Autor:innen

antibacterial agentantibioticscongenital malformationpharmacoepidemiologypregnancyquinolone

Substanzen

QuinolonesAnti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Molecular Epidemiology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
  • Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Miyagi, Japan.
  • Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan.
  • Laboratory of Biomolecule and Pathophysiological Chemistry, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Miyagi, Japan.
  • Drug Informatics, Faculty of Pharmacy, Meijo University, Nagoya, Aichi, Japan.
  • Center for Maternal and Perinatal Medicine, Tohoku University Hospital, Sendai, Miyagi, Japan.

ORCID-Profile: Kei Morishita, Ryo Obara, Aoi Noda

Förderung

  • Research Institute of Healthcare Data Science
  • Ministry of Health, Labour and Welfare of Japan
  • Ministry of Health, Labour and Welfare

Zitieren

APA

Morishita, K., Obara, T., Ishikawa, T., Obara, R., Sakai, T., Iwama, N., Shinoda, G., Noda, A., Orui, M., Ishikuro, M., Kawame, H., Mano, N., & Kuriyama, S. (2025). Association of Quinolone Exposure in the First‐Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan. Pharmacoepidemiology and Drug Safety, 34(9). https://doi.org/10.1002/pds.70190

Vancouver

Morishita K, Obara T, Ishikawa T, Obara R, Sakai T, Iwama N, et al. Association of Quinolone Exposure in the First‐Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan. Pharmacoepidemiology and Drug Safety. 2025;34(9). doi:10.1002/pds.70190

BibTeX
@article{Morishita2025,
  author = {Morishita, Kei and Obara, Taku and Ishikawa, Tomofumi and Obara, Ryo and Sakai, Takamasa and Iwama, Noriyuki and Shinoda, Genki and Noda, Aoi and Orui, Masatsugu and Ishikuro, Mami and Kawame, Hiroshi and Mano, Nariyasu and Kuriyama, Shinichi},
  title = {Association of Quinolone Exposure in the First‐Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  volume = {34},
  number = {9},
  doi = {10.1002/pds.70190}
}
Kostenlos starten →